Castle Biosciences, Inc. - CSTL STOCK NEWS

Castle Biosciences, Inc. (NASDAQ: CSTL) announced at the 2022 ACG Annual Scientific Meeting that its TissueCypher® Barrett's Esophagus Test significantly enhances management decisions for patients with low-grade dysplasia (LGD). The study showed that utilizing TissueCypher results led to a 58.4% likelihood of patients receiving appropriate management compared to 9.1% with standard care. This test aims to standardize care, reduce unnecessary therapies, and potentially lower esophageal cancer risks. The findings suggest a substantial impact on patient outcomes.

Castle Biosciences (NASDAQ: CSTL) announced positive results from its UTILISE study on DecisionDx-SCC, a test for managing cutaneous squamous cell carcinoma (cSCC). The data, shared at the 2022 Fall Clinical Dermatology Conference, indicates that over 80% of patients experienced favorable changes in management based on test results. Specifically, 42% of clinicians noted the test was the most influential factor in patient management, with 59% expressing increased confidence in treatment plans. This study aligns with prior findings on the test's clinical utility and risk stratification effectiveness.

Castle Biosciences, Inc. (NASDAQ: CSTL) announced significant findings from its DECIDE study at the 19th International Congress of the Society for Melanoma Research. The study reveals that DecisionDx-Melanoma test results influenced 85% of clinicians' decisions regarding sentinel lymph node biopsy (SLNB) procedures. Notably, the test associated with a 29% reduction in SLNBs for low-risk patients. The data emphasizes the test's role in guiding risk-aligned patient care, allowing patients with low biological risk to safely forgo SLNB, potentially avoiding unnecessary complications.

Castle Biosciences, Inc. (CSTL) will release its financial results for Q3 and the nine months ended Sept. 30, 2022, after market close on Nov. 2, 2022. The company will host a conference call at 4:30 p.m. Eastern time on the same day to discuss these results. Castle Biosciences focuses on innovative tests that guide patient care and has a portfolio that includes diagnostics for skin cancers and other conditions, with ongoing R&D for new tests targeting high clinical needs.

Castle Biosciences (CSTL) presented new data at the 30th United European Gastroenterology Week in Vienna, showing that its TissueCypher Barrett’s Esophagus Test significantly improves physician accuracy in assessing the risk of high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC) in patients with Barrett’s esophagus. Participants using TissueCypher were 65.6% more likely to predict progression to HGD or EAC, and adherence to management guidelines improved. The test is supported by multiple peer-reviewed publications and is critical for enhancing patient care and treatment strategies.

Castle Biosciences (Nasdaq: CSTL) presented a poster at the CAP22 Annual Meeting showcasing its DiffDx-Melanoma test, which demonstrated over 98% accuracy in diagnosing melanocytic lesions. The test supports decisions for local excision in challenging cases where traditional methods are inconclusive. The company’s gene expression profile tests aim to aid dermatologists in providing confident treatment plans for approximately 300,000 ambiguous lesions annually in the U.S. Detailed case study results are available in the presented poster.

Castle Biosciences, Inc. (NASDAQ: CSTL) presented impactful data at the 2022 ASDS Annual Meeting, showcasing its DecisionDx®-SCC test for cutaneous squamous cell carcinoma (SCC). This 40-gene expression profile test helps predict metastasis risk, enabling better patient management. Notably, 42% of Mohs surgeons reported increased confidence in their treatment decisions when using the test. The study revealed that familiarity with DecisionDx-SCC was high among clinicians (97%), emphasizing its role in guiding risk-aligned management strategies.

Castle Biosciences (CSTL) announced a study validating its DecisionDx-Melanoma test published in the Journal of the American Academy of Dermatology. The test integrates tumor biology with clinicopathologic factors to provide personalized risk estimates for melanoma recurrence. Key findings include that 44% of patients could avoid sentinel lymph node biopsies without compromising survival rates exceeding 98%. The proprietary algorithm demonstrated a multivariate hazard ratio of 20.00 for predicting melanoma-specific survival, suggesting enhanced decision-making in cancer management.

Castle Biosciences (Nasdaq: CSTL) presented a framework for its diagnostic gene expression profile tests, MyPath Melanoma and DiffDx-Melanoma, aimed at enhancing clinical decision-making for melanoma diagnoses during the Maui Derm NP+PA Fall 2022 Conference. The proposed clinical workflow highlights how these tests can reduce diagnostic uncertainty, particularly in distinguishing between benign and malignant melanocytic lesions. The tests demonstrated a significant reduction in unnecessary excisions for benign results and increased visits for malignant cases, thus offering personalized treatment plans.